The Peptide CDMO (Pharmaceutical) Market Size is valued at 2.5 Bn in 2024 and is predicted to reach 6.6 Bn by the year 2034 at a 10.4% CAGR during the forecast period for 2025-2034.
Peptides are bioactive molecules that bind to specific cell surface receptors, such as G protein-coupled receptors (GPCRs) or ion channels, where they trigger intracellular effects. Peptides have characteristics like safety, high specificity, and targeted drug delivery which are expected to create the future potential of expanding peptide therapeutics business. Increasing clinical demand for peptides favours the business of CDMOs.
Major driving factors of the peptide CDMO (pharmaceutical) market are the growing clinical applications of peptides, advancements in medical technologies, surging investments by pharma companies in peptides to develop drug therapies, increasing cases of chronic diseases, and a growing number of health-conscious people. Several drug-developing industries outsource their peptide production operations to CDMOs (contract research, development, and manufacturing organizations) to achieve better operational efficiency and flexibility, which is projected to propel the growth of the peptide CDMO (pharmaceutical) market in the coming years. However, the high cost of outsourced services and the need for specialized expertise for peptide production may restrict market growth during the projected period.
The peptide CDMO (pharmaceutical) market is segmented based on the scale of operation, method used, applications, synthesis types, and region. The scale of operation segment comprises preclinical/clinical and commercial. By method used, the market is classified into chemical synthesis method and non-chemical synthesis method. The market is segmented into peptide supplements, peptide vaccines, peptides as radio-theranostic agents, cell-penetrating peptides (CPPs), affinity ligands, and protein mimics based on applications. The market is divided into LPPS (liquid-phase peptide synthesis), SPPS (solid-phase peptide synthesis), and mixed-phase synthesis types. The SPPS segment is expected to dominate this market over the forecast period. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2.5 Bn |
| Revenue Forecast In 2034 | USD 6.6 Bn |
| Growth Rate CAGR | CAGR of 10.4% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Scale of Operation, Method Used, Applications, Synthesis Types, |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; Japan; Brazil; Mexico; France; Italy; Spain; India; South Korea; South East Asia |
| Competitive Landscape | AmbioPharm, Auspep, Bachem, BCN Peptide, CPC Scientific, CBL Chemical and Biopharmaceutical Laboratories, Creative Peptides, Chinese Peptide, CSBio, Corden Pharma, PolyPeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Vivitide, CreoSalus Inc., ScinoPharm, Senn Chemicals, Wuxi AppTec, Olon, Belyntic, Ferring Pharma, Numaferm, Hybio Pharmaceutical, Provepharm Life Solutions, Enzene Biosciences, Ardena Holding, Stelis Biopharma, Piramal Pharma, Space Peptides Pharmaceutical, and others. |
| Customization Scope | Free customization report with the procurement of the report; modifications to the regional and segment scope. Particular geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Peptide CDMO (Pharmaceutical) Market, by Scale of Operation,
Global Peptide CDMO (Pharmaceutical) Market, by Method Used,
Global Peptide CDMO (Pharmaceutical) Market, by By Applications,
Global Peptide CDMO (Pharmaceutical) Market, by Synthesis Types,
Global Peptide CDMO (Pharmaceutical) Market, by Region,
North America Peptide CDMO (Pharmaceutical) Market, by Country,
Europe Peptide CDMO (Pharmaceutical) Market, by Country,
Asia Pacific Peptide CDMO (Pharmaceutical) Market, by Country,
Latin America Peptide CDMO (Pharmaceutical) Market, by Country,
Middle East & Africa Peptide CDMO (Pharmaceutical) Market, by Country,
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide CDMO (Pharmaceutical) Market Snapshot
Chapter 4. Global Peptide CDMO (Pharmaceutical) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis
5.1. By Scale of Operation & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 for the following By scale of operation:
5.2.1. Preclinical / Clinical
5.2.2. Commercial
Chapter 6. Market Segmentation 2: By Applications Estimates & Trend Analysis
6.1. By Method Used & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Method Used:
6.2.1. Chemical Synthesis Method
6.2.2. Non-Chemical Synthesis Method
Chapter 7. Market Segmentation 3: By Synthesis Types Estimates & Trend Analysis
7.1. By Applications & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Applications:
7.2.1. Peptide Supplements
7.2.2. Peptide Vaccines
7.2.3. Peptides as Radio-Theranostic Agents
7.2.4. Cell Penetrating Peptides (CPPs)
7.2.5. Affinity Ligands
7.2.6. Protein Mimics
Chapter 8. Market Segmentation 4: By Synthesis Types Estimates & Trend Analysis
8.1. By Synthesis Types & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Synthesis Types
8.2.1. LPPS
8.2.2. SPPS
8.2.3. Mixed Phase
Chapter 9. Peptide CDMO (Pharmaceutical) Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
9.1.2. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts By Method Used, 2021-2034
9.1.3. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Applications, 2021-2034
9.1.4. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Synthesis Types, 2021-2034
9.1.5. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2. Europe
9.2.1. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, 2021-2034
9.2.2. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, 2021-2034
9.2.3. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, 2021-2034
9.2.4. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2021-2034
9.2.5. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, 2021-2034
9.3.2. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, 2021-2034
9.3.3. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, 2021-2034
9.3.4. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2021-2034
9.3.5. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by country, 2023-2031
9.4. Latin America
9.4.1. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
9.4.2. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, (US$ Million) 2021-2034
9.4.3. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, (US$ Million) 2021-2034
9.4.4. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Synthesis Types, 2021-2034
9.4.5. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by Country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
9.5.2. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, (US$ Million) 2021-2034
9.5.3. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, (US$ Million) 2021-2034
9.5.4. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2021-2034
9.5.5. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by Country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. AmbioPharm
10.2.2. Auspep
10.2.3. Bachem
10.2.4. BCN Peptide
10.2.5. CPC Scientific
10.2.6. CBL- Chemical and Biopharmaceutical Laboratories
10.2.7. Creative Peptides
10.2.8. Chinese Peptide
10.2.9. CSBio
10.2.10. Corden Pharma
10.2.11. PolyPeptide
10.2.12. Hybio Pharmaceutical
10.2.13. Peptide Institute
10.2.14. Pepscan
10.2.15. Almac
10.2.16. vivitide
10.2.17. CreoSalus Inc
10.2.18. ScinoPharm
10.2.19. Senn Chemicals
10.2.20. Wuxi AppTec
10.2.21. Olon
10.2.22. Belyntic
10.2.23. Ferring Pharma
10.2.24. Numaferm
10.2.25. Hybio Pharmaceutical
10.2.26. Provepharm life solutions
10.2.27. Enzene Biosciences
10.2.28. Ardena Holding
10.2.29. Stelis Biopharma
10.2.30. Piramal Pharma
10.2.31. Space Peptides Pharmaceutical
10.2.32. Other Prominent Players